GSK Demonstrates Advanced-Phase Gonorrhea Success

GSK's oral antibiotic, gepotidacin, has shown effectiveness in a late-stage gonorrhea trial, matching the current treatment regimen's success. It's also under consideration for urinary tract infections, with approvals sought later this year. Amid rising gonorrhea cases and antibiotic resistance, gepotidacin represents a new treatment avenue. It inhibits bacterial DNA replication and might be the first new antibiotic for such infections in over two decades. Full results are pending presentation, and GSK aims for approval by 2025.

The following article originally appeared in BioPharma Dive.

While treatments are available for gonorrhea, a sexually transmitted bacterial infection, cases are rising. Data from the Centers for Disease Control and Prevention show that infections in the U.S. increased by 118% between 2009 and 2021.

The bacteria that causes the infection is also becoming resistant to available medicines, creating a need for newer therapies. The World Health Organization has said that antimicrobial resistance in gonorrhea has “increased rapidly” in recent years.

Gepotidacin could become one answer to the problem. The drug is one of several GSK has been developing to combat antimicrobial resistance, and its development was aided by funding from the U.S. government.

Gepotidacin is a first-of-its-kind antibiotic designed to block the replication of bacterial DNA. It has already shown promise in testing, having succeeded in a pair of studies in uncomplicated urinary tract infections. If approved, it could be the first new antibiotic for those infections in more than 20 years.

The study in gonorrhea compared gepotidacin to ceftriaxone and azithromycin in about 600 people with uncomplicated urogenital gonorrhea caused by a type of bacteria known as Neisseria gonorrhoeae. Its goal was to prove “non-inferior” in the study.

GSK said the drug met that mark, though the press release didn’t provide specifics. The results will be disclosed at an upcoming medical meeting, the company said.

“These positive headline results demonstrate the potential for gepotidacin to provide a novel oral treatment option in the face of rising resistance and for patients who cannot take other treatments due to allergies or intolerance,” Chris Corsico, senior vice president of development at GSK, said in a statement.

The British drugmaker originally planned to seek clearance of gepotidacinin the first half of 2023, but has since pushed its timeline back and now expects an approval decision in 2025.

For more, please find the original story source here.